NCT07025226 - Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2027

Conditions

Glioma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood and CSF sample collection

DRUG

Dasatinib

Given PO

DRUG

Fisetin

Given PO

DRUG

Fluorodopa F 18

Undergo 18F-DOPA-PET scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Patient Observation

Receive rest and take no treatment

PROCEDURE

Positron Emission Tomography

Undergo 18F-DOPA-PET scan

DRUG

Quercetin

Given PO

DRUG

Temozolomide

Given PO

Trial Locations (1)

RECRUITING

Mayo Clinic in Rochester, Rochester